Inceptionr LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Inceptionr LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,923 shares of the biopharmaceutical company’s stock, valued at approximately $771,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HALO. Measured Wealth Private Client Group LLC boosted its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Abel Hall LLC increased its holdings in Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 129 shares in the last quarter. StoneX Group Inc. increased its holdings in Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 132 shares in the last quarter. Moran Wealth Management LLC lifted its stake in Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after buying an additional 151 shares during the period. Finally, Twin Capital Management Inc. lifted its stake in Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 1.3%

HALO stock opened at $81.93 on Friday. The stock’s 50 day simple moving average is $73.08 and its 200 day simple moving average is $70.58. The company has a market cap of $9.72 billion, a P/E ratio of 29.47, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a fifty-two week low of $57.67 and a fifty-two week high of $82.99.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $55,088,215. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,102 shares of company stock worth $5,205,798 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on HALO. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.